![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
January 30, 2026
This phase 3 study compares BRAF-targeted therapy (dabrafenib-trametinib) to TKI therapy (cabozantinib) in patients with disease progression after standard treatments
November 21, 2025
Timely information about research presented at medical meetings, recognition of research leaders, and more
October 17, 2025
Timely information about research presented at medical meetings, recognition of research leaders, and more
August 28, 2025
Timely information about research presented at medical meetings, recognition of research leaders, and more
July 10, 2025
The latest clinical trial findings in breast, lung, nose/sinus, and throat cancers, as well as melanoma and cancer survivorship
March 21, 2025
The changes significantly broaden eligibility and clarify key details in this phase 3 trial exploring whether adding radiation therapy to standard immunotherapy will improve survival in patients with stable disease after initial treatment
March 21, 2025
Summaries of recently published ECOG-ACRIN and PrECOG research results
February 19, 2025
Seven ground-breaking findings from cancer clinical trials in 2024 by ECOG-ACRIN and PrECOG
November 25, 2024
Fall Group Meeting highlights; impactful results in head and neck cancer; a ComboMATCH update
October 17, 2024
The changes aim to alleviate scheduling difficulties during the randomization step, and they introduce the new tumor test for this phase 2 trial testing radiotherapy with or without chemotherapy
June 11, 2024
Summaries of five ECOG-ACRIN trials presented at the 2024 American Society of Clinical Oncology Annual Meeting
April 9, 2024
Summaries of recently published ECOG-ACRIN research results